Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 91 to 100 of 471 total matches.

Juluca - A Two-Drug Complete Regimen for HIV (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018  (Issue 1561)
-1 infection who do not have a history of treatment failure or known substitutions associated ...
The FDA has approved Juluca (ViiV Healthcare/Janssen), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay) and the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (Edurant), as a once-daily complete regimen for treatment of adults with HIV-1 infection who do not have a history of treatment failure or known substitutions associated with resistance to either drug and have been taking a stable suppressive antiretroviral regimen for ≥6 months. Dolutegravir/rilpivirine is the first complete regimen to be approved for...
Med Lett Drugs Ther. 2018 Dec 3;60(1561):e202-4 | Show Introduction Hide Introduction

Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022  (Issue 1643)
from their biosimilars. Table 1. Pharmacology Class Recombinant human growth hormone Formulation 3, 3.6, 4.3, 5.2, 6.3 ...
Lonapegsomatropin-tcgd (Skytrofa – Ascendis), a long-acting prodrug of recombinant human growth hormone (rhGH), has been approved by the FDA for once-weekly subcutaneous (SC) treatment of growth failure due to inadequate secretion of endogenous growth hormone in children ≥1 year old who weigh ≥11.5 kg. It is the first once-weekly rhGH product to be approved in the US; other available rhGH formulations are administered more frequently.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):20-2 | Show Introduction Hide Introduction

Clenpiq - A Low-Volume Sodium Picosulfate-Based Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • May 21, 2018  (Issue 1547)
diagnostic yield.1-3 Colonoscopy preparations containing polyethylene glycol (PEG) plus electrolytes ...
The FDA has approved Clenpiq (Ferring), a low-volume oral solution that contains sodium picosulfate, magnesium oxide, and anhydrous citric acid, for colon cleansing prior to colonoscopy in adults. The ready-to-drink solution contains the same ingredients as Prepopik, which is supplied as a powder for reconstitution.
Med Lett Drugs Ther. 2018 May 21;60(1547):84-6 | Show Introduction Hide Introduction

Remdesivir (Veklury) for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020  (Issue 1612)
Remdesivir (Veklury) for COVID-19 Table 1. Pharmacology Class Antiviral drug Formulations 100 mg ...
The FDA has approved the antiviral drug remdesivir (Veklury – Gilead) for IV treatment of COVID-19 in hospitalized patients who are ≥12 years old and weigh ≥40 kg. Hospitalized children who are <12 years old or weigh <40 kg can receive remdesivir through an Emergency Use Authorization (EUA). Remdesivir is the first drug to be approved in the US for treatment of COVID-19.
Med Lett Drugs Ther. 2020 Nov 30;62(1612):186-8 | Show Introduction Hide Introduction

COVID-19 Updates

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022  (Issue 1646)
are moderately to severely immunocompromised1: 1. The recommended length of time between completion of a 3 ...
The CDC has issued new guidance allowing for an interval of up to 8 weeks between the first and second primary doses of an mRNA COVID-19 vaccine in certain patients 12-64 years old.1 Product labeling currently recommends a 3-week interval between the first two doses of the Pfizer/BioNTech mRNA vaccine (Comirnaty) and a 4-week interval between the first two doses of the Moderna mRNA vaccine (Spikevax). The new guidance is based on data suggesting that a longer interval can decrease the risk of myocarditis and may improve vaccine efficacy.
Med Lett Drugs Ther. 2022 Mar 21;64(1646):47-8 | Show Introduction Hide Introduction

Symfi, Symfi Lo, and Cimduo for HIV (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019  (Issue 1563)
for treatment of HIV- 1 infection. Symfiand SymfiLo (Mylan) contain the non-nucleoside reverse transcriptase ...
The FDA has approved three new once-daily fixed-dose antiretroviral drug combinations for treatment of HIV-1 infection. Symfi and Symfi Lo (Mylan) contain the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz and the nucleoside reverse transcriptase inhibitors (NRTIs) lamivudine and tenofovir disoproxil fumarate (TDF) and were approved as complete antiretroviral regimens. Symfi Lo contains a lower dose of efavirenz than both Symfi and Atripla, a fixed-dose combination of efavirenz, TDF, and the NRTI emtricitabine that was approved in 2006. Cimduo (Mylan), which...
Med Lett Drugs Ther. 2019 Jan 14;61(1563):e8-10 | Show Introduction Hide Introduction

Eravacycline (Xerava) - An IV Tetracycline for Complicated Intra-Abdominal Infections

   
The Medical Letter on Drugs and Therapeutics • Apr 22, 2019  (Issue 1570)
is available.1 Pronunciation Key Eravacycline: er” a va sye’ kleen Xerava: zuh ra’ va Summary: Eravacycline ...
Eravacycline (Xerava – Tetraphase), a new synthetic tetracycline antibiotic, has been approved by the FDA for IV treatment of complicated intra-abdominal infections (cIAIs) in adults. Eravacycline is structurally similar to tigecycline (Tygacil, and generics), a broad-spectrum tetracycline approved by the FDA for IV treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired pneumonia. A higher rate of mortality has been reported with use of tigecycline compared to other antibacterial drugs; it should be used only...
Med Lett Drugs Ther. 2019 Apr 22;61(1570):61-3 | Show Introduction Hide Introduction

Drugs for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jul 13, 2020  (Issue 1602)
between -1.0 and -2.5 and a history of fragility (low-trauma) fracture of the hip or spine, or a T-score ...
US guidelines recommend pharmacologic therapy for postmenopausal women with a bone density T-score (standard deviation from normal mean values in healthy young women) of -2.5 or below in the lumbar spine, femoral neck, total hip, or distal radius, a T-score between -1.0 and -2.5 and a history of fragility (low-trauma) fracture of the hip or spine, or a T-score between -1.0 and -2.5 and a FRAX 10-year probability of ≥3% for hip fracture or ≥20% for major osteoporotic fracture (hip, clinical spine, humerus, distal radius).
Med Lett Drugs Ther. 2020 Jul 13;62(1602):105-12 | Show Introduction Hide Introduction

Antiviral Drugs for Varicella-Zoster Virus and Herpes Simplex Virus Infections

   
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018  (Issue 1556)
are listed in tables 1 and 2. Vaccination against VZV was reviewed in a previous issue.1 VZV Infection ...
The recommendations for treatment of varicella-zoster virus (VZV) and herpes simplex virus (HSV) infections are listed in tables 1 and 2. Vaccination against VZV was reviewed in a previous issue.
Med Lett Drugs Ther. 2018 Sep 24;60(1556):153-7 | Show Introduction Hide Introduction

Ibalizumab-uiyk (Trogarzo) for Multidrug-Resistant HIV

   
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018  (Issue 1545)
of multidrugresistant HIV-1 (MDR-HIV) infection in heavily antiretroviral-experienced adults with treatment failure ...
The FDA has approved ibalizumab-uiyk (Trogarzo – Theratechnologies/TaiMed), a CD4-directed monoclonal antibody, for IV treatment of multidrug-resistant HIV-1 (MDR-HIV) infection in heavily antiretroviral-experienced adults with treatment failure on their current regimen. Ibalizumab-uiyk is the first biologic drug to be approved by the FDA for treatment of HIV-1 infection.
Med Lett Drugs Ther. 2018 Apr 23;60(1545):68-9 | Show Introduction Hide Introduction